{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:03:29Z","timestamp":1790971409344,"version":"4.1.0"},"reference-count":84,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T00:00:00Z","timestamp":1548028800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","award":["grant no. 193203"],"award-info":[{"award-number":["grant no. 193203"]}],"id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13075-018-1794-6","type":"journal-article","created":{"date-parts":[[2019,1,21]],"date-time":"2019-01-21T14:02:51Z","timestamp":1548079371000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cytosolic group IVA phospholipase A2 inhibitors, AVX001 and AVX002, ameliorate collagen-induced arthritis"],"prefix":"10.1186","volume":"21","author":[{"given":"A. J.","family":"Feuerherm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. A.","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1901-7614","authenticated-orcid":false,"given":"B.","family":"Johansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,1,21]]},"reference":[{"key":"1794_CR1","volume-title":"Kelley\u2019s textbook of rheumatology","author":"ED Harris","year":"2005","unstructured":"Harris ED, et al. Kelley\u2019s textbook of rheumatology, vol. I. Philadelphia: Elseviers Saunders; 2005."},{"issue":"1","key":"1794_CR2","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1146\/annurev.immunol.14.1.397","volume":"14","author":"M Feldmann","year":"1996","unstructured":"Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol. 1996;14(1):397\u2013440.","journal-title":"Annu Rev Immunol"},{"key":"1794_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jaut.2005.09.006","volume":"25","author":"M Feldmann","year":"2005","unstructured":"Feldmann M. Anti-TNF therapy: where have we got to in 2005? Autoimmunity. 2005;25:26\u20138.","journal-title":"Autoimmunity"},{"issue":"suppl 5","key":"1794_CR4","doi-asserted-by":"publisher","first-page":"v3","DOI":"10.1093\/rheumatology\/kes113","volume":"51","author":"E Choy","year":"2012","unstructured":"Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology. 2012;51(suppl 5):v3\u2013v11.","journal-title":"Rheumatology"},{"issue":"3","key":"1794_CR5","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.4049\/jimmunol.163.3.1521","volume":"163","author":"P Charles","year":"1999","unstructured":"Charles P, et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNFa therapy in rheumatoid arthritis. J Immunol. 1999;163(3):1521\u20138.","journal-title":"J Immunol"},{"issue":"1","key":"1794_CR6","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1002\/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L","volume":"43","author":"PC Taylor","year":"2000","unstructured":"Taylor PC, et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor \u03b1 blockade in patients with rheumatoid arthritis. Arthritis Rheum. 2000;43(1):38\u201347.","journal-title":"Arthritis Rheum"},{"issue":"6","key":"1794_CR7","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1093\/rheumatology\/36.6.643","volume":"36","author":"FM Brennan","year":"1997","unstructured":"Brennan FM, et al. Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy. Rheumatology. 1997;36(6):643\u201350.","journal-title":"Rheumatology"},{"issue":"38","key":"1794_CR8","doi-asserted-by":"publisher","first-page":"35344","DOI":"10.1074\/jbc.M105264200","volume":"276","author":"MW Anthonsen","year":"2001","unstructured":"Anthonsen MW, et al. Atypical lambda \/iota PKC conveys 5-lipoxygenase\/leukotriene B4-mediated cross-talk between phospholipase A2s regulating NF-kappa B activation in response to tumor necrosis factor-alpha and interleukin-1beta. J Biol Chem. 2001;276(38):35344\u201351.","journal-title":"J Biol Chem"},{"issue":"32","key":"1794_CR9","doi-asserted-by":"publisher","first-page":"30527","DOI":"10.1074\/jbc.M008481200","volume":"276","author":"MW Anthonsen","year":"2001","unstructured":"Anthonsen MW, Solhaug A, Johansen B. Functional coupling between secretory and cytosolic phospholipase a2 modulates tumor necrosis factor-alpha - and interleukin-1beta -induced NF-kappa B activation. J Biol Chem. 2001;276(32):30527\u201336.","journal-title":"J Biol Chem"},{"issue":"4","key":"1794_CR10","doi-asserted-by":"publisher","first-page":"308","DOI":"10.3109\/03009742.2010.547872","volume":"40","author":"L Leistad","year":"2011","unstructured":"Leistad L, et al. Multiple phospholipase A2 enzymes participate in the inflammatory process in osteoarthritic cartilage. Scand J Rheumatol. 2011;40(4):308\u201316.","journal-title":"Scand J Rheumatol"},{"issue":"8","key":"1794_CR11","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1111\/j.1476-5381.2012.02114.x","volume":"167","author":"A Huwiler","year":"2012","unstructured":"Huwiler A, et al. The \u03c93-polyunsaturated fatty acid derivatives AVX001 and AVX002 directly inhibit cytosolic phospholipase A2 and suppress PGE2 formation in mesangial cells. Br J Pharmacol. 2012;167(8):1691\u2013701.","journal-title":"Br J Pharmacol"},{"issue":"12","key":"1794_CR12","doi-asserted-by":"publisher","first-page":"e83555","DOI":"10.1371\/journal.pone.0083555","volume":"8","author":"RM Sommerfelt","year":"2013","unstructured":"Sommerfelt RM, et al. Cytosolic phospholipase A2 regulates TNF-induced production of joint destructive effectors in synoviocytes. PLoS One. 2013;8(12):e83555.","journal-title":"PLoS One"},{"issue":"4","key":"1794_CR13","doi-asserted-by":"publisher","first-page":"e0119088","DOI":"10.1371\/journal.pone.0119088","volume":"10","author":"RM Sommerfelt","year":"2015","unstructured":"Sommerfelt RM, et al. Cytosolic phospholipase A2 modulates TLR2 signaling in synoviocytes. PLoS One. 2015;10(4):e0119088.","journal-title":"PLoS One"},{"issue":"Supplement","key":"1794_CR14","doi-asserted-by":"publisher","first-page":"S237","DOI":"10.1194\/jlr.R800033-JLR200","volume":"50","author":"JE Burke","year":"2009","unstructured":"Burke JE, Dennis EA. Phospholipase A2 structure\/function, mechanism, and signaling. J Lipid Res. 2009;50(Supplement):S237\u201342.","journal-title":"J Lipid Res"},{"issue":"2\u20133","key":"1794_CR15","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/0929-7855(95)00012-F","volume":"12","author":"JD Clark","year":"1995","unstructured":"Clark JD, et al. Cytosolic phospholipase A2. J Lipid Mediat Cell Signal. 1995;12(2\u20133):83\u2013117.","journal-title":"J Lipid Mediat Cell Signal"},{"issue":"6","key":"1794_CR16","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1016\/0092-8674(91)90556-E","volume":"65","author":"JD Clark","year":"1991","unstructured":"Clark JD, et al. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca2+\u2212dependent translocation domain with homology to PKC and GAP. Cell. 1991;65(6):1043\u201351.","journal-title":"Cell"},{"issue":"1\u20132","key":"1794_CR17","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1388-1981(00)00116-5","volume":"1488","author":"A Sapirstein","year":"2000","unstructured":"Sapirstein A, Bonventre JV. Specific physiological roles of cytosolic phospholipase A2 as defined by gene knockouts. Biochim Biophys Acta. 2000;1488(1\u20132):139\u201348.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"1794_CR18","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2174\/187153006779025711","volume":"6","author":"J Akaogi","year":"2006","unstructured":"Akaogi J, et al. Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy. Endocr Metab Immune Disord Drug Targets. 2006;6(4):383\u201394.","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"issue":"3","key":"1794_CR19","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0049-0172(03)00134-3","volume":"33","author":"J Martel-Pelletier","year":"2003","unstructured":"Martel-Pelletier J, Pelletier JP, Fahmi H. Cyclooxygenase-2 and prostaglandins in articular tissues. Semin Arthritis Rheum. 2003;33(3):155\u201367.","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"1794_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1254\/jphs.09R03CP","volume":"112","author":"D Sakata","year":"2010","unstructured":"Sakata D, Yao C, Narumiya S. Prostaglandin E2, an immunoactivator. J Pharmacol Sci. 2010;112(1):1\u20135.","journal-title":"J Pharmacol Sci"},{"issue":"Suppl 1","key":"1794_CR21","first-page":"3","volume":"50","author":"B Samuelsson","year":"1991","unstructured":"Samuelsson B. Arachidonic acid metabolism: role in inflammation. Z Rheumatol. 1991;50(Suppl 1):3\u20136.","journal-title":"Z Rheumatol"},{"issue":"8","key":"1794_CR22","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1001\/jama.286.8.954","volume":"286","author":"D Mukherjee","year":"2001","unstructured":"Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8):954\u20139.","journal-title":"JAMA"},{"issue":"4","key":"1794_CR23","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1053\/gast.2002.36013","volume":"123","author":"L Laine","year":"2002","unstructured":"Laine L, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterol. 2002;123(4):1006\u201312.","journal-title":"Gastroenterol"},{"issue":"1","key":"1794_CR24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1742-7843.2007.00149.x","volume":"102","author":"K Vuolteenaho","year":"2008","unstructured":"Vuolteenaho K, Moilanen T, Moilanen E. Non-steroidal anti-inflammatory drugs, cyclooxygenase-2 and the bone healing process. Basic Clin Pharmacol Toxicol. 2008;102(1):10\u20134.","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"1794_CR25","doi-asserted-by":"publisher","first-page":"c7086","DOI":"10.1136\/bmj.c7086","volume":"342","author":"S Trelle","year":"2011","unstructured":"Trelle S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086.","journal-title":"BMJ"},{"issue":"9","key":"1794_CR26","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.amjcard.2009.01.014","volume":"103","author":"ME Farkouh","year":"2009","unstructured":"Farkouh ME, Greenberg BP. An evidence-based review of the cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Cardiol. 2009;103(9):1227\u201337.","journal-title":"Am J Cardiol"},{"issue":"25","key":"1794_CR27","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/newbio231232a0","volume":"231","author":"J Vane","year":"1971","unstructured":"Vane J. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231(25):232\u20135.","journal-title":"Nat New Biol"},{"issue":"6","key":"1794_CR28","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00296-011-2263-6","volume":"32","author":"P Conaghan","year":"2012","unstructured":"Conaghan P. A turbulent decade for NSAIDs: update on current concepts of classification, epidemiology, comparative efficacy, and toxicity. Rheumatol Int. 2012;32(6):1491\u2013502.","journal-title":"Rheumatol Int"},{"issue":"1","key":"1794_CR29","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1136\/annrheumdis-2016-209775","volume":"76","author":"R Agca","year":"2017","unstructured":"Agca R, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015\/2016 update. Ann Rheum Dis. 2017;76(1):17\u201328.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"1794_CR30","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","volume":"76","author":"JS Smolen","year":"2017","unstructured":"Smolen JS, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017;76(6):960\u201377.","journal-title":"Ann Rheum Dis"},{"key":"1794_CR31","doi-asserted-by":"crossref","unstructured":"Visser K, van der Heijde D. Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis. 2009;68(7):1094-9.","DOI":"10.1136\/ard.2008.092668"},{"issue":"12","key":"1794_CR32","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1136\/annrheumdis-2013-203485","volume":"72","author":"P Emery","year":"2013","unstructured":"Emery P, Sebba A, Huizinga TWJ. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis. 2013;72(12):1897\u2013904.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1794_CR33","first-page":"204","volume":"71","author":"JU Scher","year":"2013","unstructured":"Scher JU. Monotherapy in rheumatoid arthritis. Bull Hosp Jt Dis. 2013;71(3):204\u20137.","journal-title":"Bull Hosp Jt Dis"},{"issue":"6","key":"1794_CR34","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/S1568-9972(03)00048-X","volume":"2","author":"AG Suryaprasad","year":"2003","unstructured":"Suryaprasad AG, Prindiville T. The biology of TNF blockade. Autoimmun Rev. 2003;2(6):346\u201357.","journal-title":"Autoimmun Rev"},{"issue":"2","key":"1794_CR35","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","volume":"72","author":"FB Vincent","year":"2013","unstructured":"Vincent FB, et al. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72(2):165\u201378.","journal-title":"Ann Rheum Dis"},{"key":"1794_CR36","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","volume":"295","author":"TA Bongartz","year":"2006","unstructured":"Bongartz TA, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275\u201385.","journal-title":"JAMA"},{"issue":"3","key":"1794_CR37","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/art.30174","volume":"63","author":"G Courties","year":"2011","unstructured":"Courties G, et al. Cytosolic phospholipase A2alpha gene silencing in the myeloid lineage alters development of Th1 responses and reduces disease severity in collagen-induced arthritis. Arthritis Rheum. 2011;63(3):681\u201390.","journal-title":"Arthritis Rheum"},{"issue":"10","key":"1794_CR38","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1084\/jem.20030016","volume":"197","author":"M Hegen","year":"2003","unstructured":"Hegen M, et al. Cytosolic phospholipase A2{alpha}-deficient mice are resistant to collagen-induced arthritis. J Exp Med. 2003;197(10):1297\u2013302.","journal-title":"J Exp Med"},{"key":"1794_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/eji.200838545","volume":"38","author":"L Raichel","year":"2008","unstructured":"Raichel L, et al. Reduction of cPLA2alpha overexpression: an efficient anti-inflammatory therapy for collagen-induced arthritis. Eur J Immunol. 2008;38:1\u201311.","journal-title":"Eur J Immunol"},{"issue":"1","key":"1794_CR40","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s00011-009-0069-8","volume":"59","author":"N Tai","year":"2010","unstructured":"Tai N, et al. Cytosolic phospholipase A2 alpha inhibitor, pyrroxyphene, displays anti-arthritic and anti-bone destructive action in a murine arthritis model. Inflamm Res. 2010;59(1):53\u201362.","journal-title":"Inflamm Res"},{"issue":"23","key":"1794_CR41","doi-asserted-by":"publisher","first-page":"5935","DOI":"10.1021\/bi00074a003","volume":"32","author":"IP Street","year":"1993","unstructured":"Street IP, et al. Slow- and tight-binding inhibitors of the 85-kDa human phospholipase A2. Biochemistry. 1993;32(23):5935\u201340.","journal-title":"Biochemistry"},{"issue":"10","key":"1794_CR42","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1021\/cr200085w","volume":"111","author":"EA Dennis","year":"2011","unstructured":"Dennis EA, et al. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev. 2011;111(10):6130\u201385.","journal-title":"Chem Rev"},{"issue":"1","key":"1794_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1517\/13543770903463905","volume":"20","author":"V Magrioti","year":"2010","unstructured":"Magrioti V, Kokotos G. Phospholipase A2 inhibitors as potential therapeutic agents for the treatment of inflammatory diseases. Expert Opin Ther Pat. 2010;20(1):1\u201318.","journal-title":"Expert Opin Ther Pat"},{"issue":"3","key":"1794_CR44","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1517\/13543776.2013.754425","volume":"23","author":"V Magrioti","year":"2013","unstructured":"Magrioti V, Kokotos G. Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010--present). Expert Opin Ther Pat. 2013;23(3):333\u201344.","journal-title":"Expert Opin Ther Pat"},{"issue":"2","key":"1794_CR45","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/13543776.2017.1246540","volume":"27","author":"MG Kokotou","year":"2017","unstructured":"Kokotou MG, et al. Inhibitors of phospholipase A2 and their therapeutic potential: an update on patents (2012-2016). Expert Opin Ther Pat. 2017;27(2):217\u201325.","journal-title":"Expert Opin Ther Pat"},{"issue":"7","key":"1794_CR46","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1136\/annrheumdis-2013-204627","volume":"73","author":"M Cross","year":"2014","unstructured":"Cross M, et al. The global burden of rheumatoid arthritis: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73(7):1316\u201322.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"1794_CR47","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1136\/annrheumdis-2013-204588","volume":"73","author":"C Gaujoux-Viala","year":"2014","unstructured":"Gaujoux-Viala C, et al. Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):510\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"9602","key":"1794_CR48","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1016\/S0140-6736(07)60784-3","volume":"370","author":"JS Smolen","year":"2007","unstructured":"Smolen JS, et al. New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370(9602):1861\u201374.","journal-title":"Lancet"},{"key":"1794_CR49","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1741-7015-12-43","volume":"12","author":"A Mocsai","year":"2014","unstructured":"Mocsai A, Kovacs L, Gergely P. What is the future of targeted therapy in rheumatology: biologics or small molecules? BMC Med. 2014;12:43.","journal-title":"BMC Med"},{"issue":"18","key":"1794_CR50","doi-asserted-by":"publisher","first-page":"7523","DOI":"10.1021\/jm500192s","volume":"57","author":"G Kokotos","year":"2014","unstructured":"Kokotos G, et al. Inhibition of group IVA cytosolic phospholipase A2 by thiazolyl ketones in vitro, ex vivo, and in vivo. J Med Chem. 2014;57(18):7523\u201335.","journal-title":"J Med Chem"},{"issue":"1","key":"1794_CR51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12885-015-2026-y","volume":"16","author":"E Kim","year":"2016","unstructured":"Kim E, et al. Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model. BMC Cancer. 2016;16(1):1\u201311.","journal-title":"BMC Cancer"},{"key":"1794_CR52","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1084\/jem.146.3.857","volume":"146","author":"DE Trentham","year":"1997","unstructured":"Trentham DE, Townes AS, Kang AH. Autoimmunity to type II collagen an experimental model of arthritis. J Exp Med. 1997;146:857\u201368.","journal-title":"J Exp Med"},{"issue":"11","key":"1794_CR53","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1136\/ard.2007.076430","volume":"67","author":"M Hegen","year":"2008","unstructured":"Hegen M, et al. Utility of animal models for identification of potential therapeutics for rheumatoid arthritis. Ann Rheum Dis. 2008;67(11):1505\u201315.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"1794_CR54","first-page":"1","volume":"15","author":"EF Rosloniec","year":"2010","unstructured":"Rosloniec EF, et al. Collagen-induced arthritis. Curr Protoc Immunol. 2010;15(5):1\u201325.","journal-title":"Curr Protoc Immunol"},{"issue":"14","key":"1794_CR55","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1039\/b001944p","volume":"1","author":"AK Holmeide","year":"2000","unstructured":"Holmeide AK, Skattebol L. Syntheses of some polyunsaturated trifluoromethyl ketones as potential phospholipase A(2) inhibitors. J Chem Soc Perkin Trans. 2000;1(14):2271\u20136.","journal-title":"J Chem Soc Perkin Trans"},{"issue":"2","key":"1794_CR56","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1006\/abio.1999.4053","volume":"269","author":"H-C Yang","year":"1999","unstructured":"Yang H-C, et al. Group-specific assays that distinguish between the four major types of mammalian phospholipase A2. Anal Biochem. 1999;269(2):278\u201388.","journal-title":"Anal Biochem"},{"issue":"14","key":"1794_CR57","doi-asserted-by":"publisher","first-page":"3615","DOI":"10.1021\/jm030485c","volume":"47","author":"G Kokotos","year":"2004","unstructured":"Kokotos G, et al. Inhibition of group IVA Cytosolic phospholipase A2 by novel 2-oxoamides in vitro, in cells, and in vivo. J Med Chem. 2004;47(14):3615\u201328.","journal-title":"J Med Chem"},{"issue":"1\u20134","key":"1794_CR58","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.prostaglandins.2005.02.004","volume":"77","author":"KK Lucas","year":"2005","unstructured":"Lucas KK, Dennis EA. Distinguishing phospholipase A2 types in biological samples by employing group-specific assays in the presence of inhibitors. Prostaglandins Other Lipid Mediat. 2005;77(1\u20134):235\u201348.","journal-title":"Prostaglandins Other Lipid Mediat"},{"key":"1794_CR59","unstructured":"EMEA. Non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals. ICH M3 (R2). European Medicines Agency; 2009. p. 1\u201325. https:\/\/www.ema.europa.eu\/ ."},{"issue":"3","key":"1794_CR60","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejphar.2006.03.018","volume":"539","author":"R Malaviya","year":"2006","unstructured":"Malaviya R, et al. Targeting cytosolic phospholipase A2 by arachidonyl trifluoromethyl ketone prevents chronic inflammation in mice. Eur J Pharmacol. 2006;539(3):195\u2013204.","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"1794_CR61","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1084\/jem.154.3.688","volume":"154","author":"PH Wooley","year":"1981","unstructured":"Wooley PH, et al. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J Exp Med. 1981;154(3):688\u2013700.","journal-title":"J Exp Med"},{"issue":"7","key":"1794_CR62","doi-asserted-by":"crossref","first-page":"3421","DOI":"10.4049\/jimmunol.161.7.3421","volume":"161","author":"L Thommesen","year":"1998","unstructured":"Thommesen L, et al. Selective inhibitors of cytosolic or secretory phospholipase A2 block TNF-induced activation of transcription factor nuclear factor-{kappa}B and expression of ICAM-1. J Immunol. 1998;161(7):3421\u201330.","journal-title":"J Immunol"},{"issue":"5","key":"1794_CR63","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1038\/nprot.2007.173","volume":"2","author":"DD Brand","year":"2007","unstructured":"Brand DD, Latham KA, Rosloniec EF. Collagen-induced arthritis. Nat Protocols. 2007;2(5):1269\u201375.","journal-title":"Nat Protocols"},{"issue":"8","key":"1794_CR64","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1002\/art.22794","volume":"56","author":"AF Sheibanie","year":"2007","unstructured":"Sheibanie AF, et al. Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23\/interleukin-17 axis. Arthritis Rheum. 2007;56(8):2608\u201319.","journal-title":"Arthritis Rheum"},{"issue":"20","key":"1794_CR65","doi-asserted-by":"publisher","first-page":"9784","DOI":"10.1073\/pnas.89.20.9784","volume":"89","author":"RO Williams","year":"1992","unstructured":"Williams RO, Feldmann M, Maini RN. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A. 1992;89(20):9784\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"1794_CR66","first-page":"2092","volume":"23","author":"GS Novaes","year":"1996","unstructured":"Novaes GS, et al. Low dose methotrexate decreases intraarticular prostaglandin and interleukin 1 levels in antigen induced arthritis in rabbits. J Rheumatol. 1996;23(12):2092\u20137.","journal-title":"J Rheumatol"},{"issue":"5","key":"1794_CR67","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/S8756-3282(97)00023-9","volume":"20","author":"Y Segawa","year":"1997","unstructured":"Segawa Y, et al. Methotrexate maintains bone mass by preventing both a decrease in bone formation and an increase in bone resorption in adjuvant-induced arthritic rats. Bone. 1997;20(5):457\u201364.","journal-title":"Bone"},{"issue":"3","key":"1794_CR68","first-page":"433","volume":"25","author":"P Vergne","year":"1998","unstructured":"Vergne P, et al. Methotrexate and cyclooxygenase metabolism in cultured human rheumatoid synoviocytes. J Rheumatol. 1998;25(3):433\u201340.","journal-title":"J Rheumatol"},{"issue":"4","key":"1794_CR69","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1093\/rheumatology\/40.4.375","volume":"40","author":"AS Williams","year":"2001","unstructured":"Williams AS, et al. Amelioration of rat antigen-induced arthritis by liposomally conjugated methotrexate is accompanied by down-regulation of cytokine mRNA expression. Rheumatology (Oxford). 2001;40(4):375\u201383.","journal-title":"Rheumatology (Oxford)"},{"issue":"5 Suppl 2","key":"1794_CR70","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1053\/sarh.2001.23704","volume":"30","author":"WB Berg van den","year":"2001","unstructured":"van den Berg WB. Uncoupling of inflammatory and destructive mechanisms in arthritis. Semin Arthritis Rheum. 2001;30(5 Suppl 2):7\u201316.","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"1794_CR71","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.4049\/jimmunol.163.9.5049","volume":"163","author":"LA Joosten","year":"1999","unstructured":"Joosten LA, et al. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J Immunol. 1999;163(9):5049\u201355.","journal-title":"J Immunol"},{"issue":"12","key":"1794_CR72","doi-asserted-by":"publisher","first-page":"7240","DOI":"10.4049\/jimmunol.165.12.7240","volume":"165","author":"RO Williams","year":"2000","unstructured":"Williams RO, et al. Evaluation of TNF-alpha and IL-1 blockade in collagen-induced arthritis and comparison with combined anti-TNF-alpha\/anti-CD4 therapy. J Immunol. 2000;165(12):7240\u20135.","journal-title":"J Immunol"},{"issue":"5","key":"1794_CR73","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/rheumatology\/39.5.533","volume":"39","author":"SBV Mello","year":"2000","unstructured":"Mello SBV, et al. Methotrexate as a preferential cyclooxygenase 2 inhibitor in whole blood of patients with rheumatoid arthritis. Rheumatology. 2000;39(5):533\u20136.","journal-title":"Rheumatology"},{"issue":"12","key":"1794_CR74","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1007\/s00011-011-0385-7","volume":"60","author":"AD Mancini","year":"2011","unstructured":"Mancini AD, Di Battista JA. The cardinal role of the phospholipase A(2)\/cyclooxygenase-2\/prostaglandin E synthase\/prostaglandin E(2) (PCPP) axis in inflammostasis. Inflamm Res. 2011;60(12):1083\u201392.","journal-title":"Inflamm Res"},{"issue":"1","key":"1794_CR75","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.0105-2896.2009.00859.x","volume":"233","author":"B Bartok","year":"2010","unstructured":"Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev. 2010;233(1):233\u201355.","journal-title":"Immunol Rev"},{"issue":"1","key":"1794_CR76","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.advms.2017.06.004","volume":"63","author":"M Hoxha","year":"2018","unstructured":"Hoxha M. A systematic review on the role of eicosanoid pathways in rheumatoid arthritis. Adv Med Sci. 2018;63(1):22\u20139.","journal-title":"Adv Med Sci"},{"issue":"7","key":"1794_CR77","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/S0167-5699(97)01087-6","volume":"18","author":"SW Edwards","year":"1997","unstructured":"Edwards SW, Hallett MB. Seeing the wood for the trees: the forgotten role of neutrophils in rheumatoid arthritis. Immunol Today. 1997;18(7):320\u20134.","journal-title":"Immunol Today"},{"issue":"10","key":"1794_CR78","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/nrrheum.2014.80","volume":"10","author":"HL Wright","year":"2014","unstructured":"Wright HL, Moots RJ, Edwards SW. The multifactorial role of neutrophils in rheumatoid arthritis. Nat Rev Rheumatol. 2014;10(10):593\u2013601.","journal-title":"Nat Rev Rheumatol"},{"key":"1794_CR79","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1182\/blood-2004-12-4942","volume":"106","author":"L Yang","year":"2005","unstructured":"Yang L, et al. ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-\u03b1-activated vascular endothelium under flow. Blood. 2005;106:584\u201392.","journal-title":"Blood"},{"issue":"1","key":"1794_CR80","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1053\/joca.1999.0266","volume":"8","author":"M Miwa","year":"2000","unstructured":"Miwa M, et al. Induction of apoptosis in bovine articular chondrocyte by prostaglandin E2 through cAMP-dependent pathway. Osteoarthr Cartil. 2000;8(1):17\u201324.","journal-title":"Osteoarthr Cartil"},{"issue":"10","key":"1794_CR81","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1084\/jem.20030015","volume":"197","author":"C Miyaura","year":"2003","unstructured":"Miyaura C, et al. An essential role of cytosolic phospholipase A2-alpha in prostaglandin E2-mediated bone resorption associated with inflammation. J Exp Med. 2003;197(10):1303\u201310.","journal-title":"J Exp Med"},{"issue":"3","key":"1794_CR82","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrc2809","volume":"10","author":"D Wang","year":"2010","unstructured":"Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer. 2010;10(3):181\u201393.","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"1794_CR83","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1096\/fj.15-278416","volume":"30","author":"SM Naini","year":"2016","unstructured":"Naini SM, et al. Cytosolic phospholipase A2alpha regulates G1 progression through modulating FOXO1 activity. FASEB J. 2016;30(3):1155\u201370.","journal-title":"FASEB J"},{"issue":"21","key":"1794_CR84","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1128\/MCB.00184-15","volume":"35","author":"SM Naini","year":"2015","unstructured":"Naini SM, et al. Group IVA cytosolic phospholipase A2 regulates the G2-to-M transition by modulating the activity of tumor suppressor SIRT2. Mol Cell Biol. 2015;35(21):3768\u201384.","journal-title":"Mol Cell Biol"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1794-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13075-018-1794-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-018-1794-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T07:14:26Z","timestamp":1720941266000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-018-1794-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,21]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1794"],"URL":"https:\/\/doi.org\/10.1186\/s13075-018-1794-6","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,21]]},"assertion":[{"value":"13 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with Shanghai Medicilon Inc. standard operating procedures (SOPs). This study would not be considered within the scope of the Good Laboratory Practice Regulations.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"EA Dennis is scientific board member of Avexxin AS, B Johansen is CSO of Avexxin AS, and AJ Feuerherm is partly employed by Avexxin AS.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"29"}}